RxDoctor Payments Data

Joseph Schirripa, MD

Nephrology · Brick, NJNPI 1609804384

Payments from drug & device makers

$4,143in general payments, 2019–2025

Across 205 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Vifor Pharma, Inc.$688
  • Otsuka America Pharmaceutical, Inc.$412
  • GSK$246
  • Ardelyx, Inc.$243
  • Daiichi Sankyo Inc.$217
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,02697%
  • Education$1183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,143 in reported general payments places this provider in the 80th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$315,947
Medicare patients
839
Services billed
2,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$263,574
FarxigaDapagliflozin Propanediol226$235,571
JardianceEmpagliflozin58$83,424
VeltassaPatiromer Calcium Sorbitex39$45,380
KerendiaFinerenone22$23,174
Potassium Citrate ErPotassium Citrate61$9,459
Cinacalcet Hcl11$7,037
Irbesartan143$4,959
Sevelamer Carbonate39$4,356
Torsemide229$4,345
Calcitriol155$3,556
Eplerenone13$3,033
Potassium Chloride111$2,616
Febuxostat13$2,536
Chlorthalidone127$2,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$412$263,57413 claims
AstraZenecaFarxiga$1,164$235,571226 claims
Boehringer IngelheimJardiance$66$83,42458 claims
BayerKerendia$202$23,17422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →